Equities Analysts Offer Predictions for BHC FY2025 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Analysts at Zacks Research reduced their FY2025 EPS estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Monday, January 20th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $4.23 per share for the year, down from their previous forecast of $4.28. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.27 EPS and FY2026 earnings at $4.90 EPS.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the prior year, the firm earned $1.03 earnings per share. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year.

A number of other research firms have also issued reports on BHC. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Finally, Royal Bank of Canada lifted their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Bausch Health Companies currently has a consensus rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Stock Down 1.1 %

Shares of NYSE:BHC opened at $7.73 on Thursday. The company has a market capitalization of $2.79 billion, a P/E ratio of -16.09 and a beta of 0.69. Bausch Health Companies has a 52-week low of $3.96 and a 52-week high of $11.46. The stock’s fifty day simple moving average is $7.83 and its 200-day simple moving average is $7.46.

Hedge Funds Weigh In On Bausch Health Companies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldentree Asset Management LP grew its stake in shares of Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock valued at $239,552,000 after buying an additional 6,958,717 shares during the period. Bank of Montreal Can grew its position in Bausch Health Companies by 234.0% during the third quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock valued at $31,598,000 after acquiring an additional 2,685,675 shares during the period. SG Americas Securities LLC increased its stake in Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after acquiring an additional 1,263,706 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Bausch Health Companies by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock worth $22,063,000 after purchasing an additional 341,936 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in shares of Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after purchasing an additional 1,252,834 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.